SL 801

Drug Profile

SL 801

Alternative Names: CBS 9106; SL-801

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator CanBas
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell cycle modulators; Exportin-1 protein inhibitors; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Haematological malignancies; Multiple myeloma

Most Recent Events

  • 03 Dec 2016 Pharmacokineics and pharmacodynamics data from in vitro studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 02 Dec 2016 Preclinical trials in Haematological malignancies (Combination therapy) in USA
  • 02 Dec 2016 Preclinical trials in Multiple myeloma (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top